Detalhe da pesquisa
1.
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
Eur J Nucl Med Mol Imaging
; 51(3): 885-895, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889298
2.
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
Eur J Nucl Med Mol Imaging
; 50(9): 2899-2909, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37148297
3.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246997
4.
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me.
Mol Pharm
; 20(12): 6463-6473, 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978936
5.
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
Eur J Nucl Med Mol Imaging
; 49(5): 1584-1594, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34725725
6.
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Eur J Nucl Med Mol Imaging
; 49(3): 1075-1085, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34494131
7.
[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.
Eur J Nucl Med Mol Imaging
; 49(13): 4736-4747, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930033
8.
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Eur J Nucl Med Mol Imaging
; 49(6): 2064-2076, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932154
9.
Benefit of including CT urography in [68Ga]PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis.
Q J Nucl Med Mol Imaging
; 66(3): 280-289, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31992688
10.
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
J Urol
; 206(1): 88-96, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617326
11.
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
Eur J Nucl Med Mol Imaging
; 48(1): 103-112, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378019
12.
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.
Eur J Nucl Med Mol Imaging
; 47(3): 721-728, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31758224
13.
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Eur J Nucl Med Mol Imaging
; 47(3): 687-694, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31901103
14.
Striatal dopamine transporters and cognitive function in Parkinson's disease.
Acta Neurol Scand
; 142(4): 385-391, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914881
15.
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.
Eur J Nucl Med Mol Imaging
; 46(5): 1102-1110, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30637501
16.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 46(12): 2536-2544, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31440799
17.
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
Eur J Nucl Med Mol Imaging
; 45(5): 846-859, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453701
18.
Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies.
Eur J Nucl Med Mol Imaging
; 45(10): 1721-1730, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29516130
19.
Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me.
Org Biomol Chem
; 16(40): 7503-7512, 2018 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30276385
20.
Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
Eur J Nucl Med Mol Imaging
; 44(2): 190-195, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530124